Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Neurodegenerative disease

A neural stem-cell treatment for progressive multiple sclerosis

Nature Medicine volume 29, pages 27–28 (2023)Cite this article

Subjects

A phase 1 trial using an allogeneic stem-cell-based therapy in people with progressive multiple sclerosis (MS) shows the feasibility and tolerability of the approach; rigorous evaluation of this and other regenerative strategies for MS is now urgently needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematics of the phase 1 STEMS clinical trial in people with progressive multiple sclerosis.

References

  1. Pluchino, S., Smith, J. A. & Peruzzotti-Jametti, L. Trends Mol. Med. 26, 898–912 (2020).

    Article  CAS  Google Scholar 

  2. Genchi, E., Brambilla, E., Sangalli, F. & Martino, G. Nat. Med. https://doi.org/10.1038/s41591-022-02097-3 (2023).

  3. Lindvall, O. et al. Lancet 332, 1483–1484 (1988).

    Article  Google Scholar 

  4. Mazzini, L. et al. Stem Cells Transl. Med. 8, 887–897 (2019).

    Article  Google Scholar 

  5. Baloh, R. H. et al. Nat. Med. 28, 1813–1822 (2022).

    Article  CAS  Google Scholar 

  6. Leone, M. et al. Preprint at http://medrxiv.org/lookup/doi/10.1101/2022.11.14.22282124 (2022).

  7. Harris, V. K. et al. Neurol. Neuroimmunol. Neuroinflamm. 8, e928 (2021).

    Article  Google Scholar 

  8. Petrou, P. et al. Brain 143, 3574–3588 (2020).

    Article  Google Scholar 

  9. Uccelli, A. et al. Lancet Neurol. 20, 917–929 (2021).

    Article  CAS  Google Scholar 

  10. Yamanaka, S. Cell Stem Cell 27, 523–531 (2020).

    Article  CAS  Google Scholar 

  11. Deinsberger, J., Reisinger, D. & Weber, B. NPJ Regen. Med. 5, 15 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The New York Stem Cell Foundation Research Institute, New York, NY, USA

    Valentina Fossati

  2. Department of Clinical Neurosciences and NIHR Biomedical Research Centre, University of Cambridge, Cambridge, UK

    Luca Peruzzotti-Jametti & Stefano Pluchino

Authors
  1. Valentina Fossati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Peruzzotti-Jametti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefano Pluchino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentina Fossati.

Ethics declarations

Competing interests

S.P. is founder, chief scientific officer and shareholder (>5%) of CITC Ltd and chair of the scientific advisory board at ReNeuron plc. The other authors have no conflicts to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fossati, V., Peruzzotti-Jametti, L. & Pluchino, S. A neural stem-cell treatment for progressive multiple sclerosis. Nat Med 29, 27–28 (2023). https://doi.org/10.1038/s41591-022-02164-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-022-02164-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing